クロルイミプラミン·塩酸塩
アナフラニール · クロミプラミン·塩酸塩 · クロミプラミン塩酸塩 · 塩酸クロルイミプラミン · 3-[(3-クロロ-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン)-5-イル]-N,N-ジメチル-プロパン-1-アミン·塩酸塩 · 塩酸クロミプラミン · 3-クロロ-5-(3-ジメチルアミノプロピル)-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン·塩酸塩 · アナフラニル
識別子と物理属性
| CAS No. | 17321-77-6 |
|---|---|
| 分子式 | C19H24Cl2N2 |
| 平均分子量 | 351.3 g/mol |
| 単同位体質量 | 350.1316542 g/mol |
| SMILES | CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21.Cl |
| InChIKey | WIMWMKZEIBHDTH-UHFFFAOYSA-N |
| PubChem CID | 68539 |
| ChEMBL | CHEMBL1200710 |
| ChEBI | CHEBI:3755 |
| EC No. | 241-344-3 |
| DTXSID | DTXSID3042633 |
| 現地名 | クロルイミプラミン·塩酸塩 |
化学・物理的性質
| 極性表面積 | 6.5 |
|---|---|
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 2 |
| 回転可能結合数 | 4 |
| 重原子数 | 23 |
| 形式電荷 | 0 |
| 複雑度 | 346 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Animal Drugs | EMA approved medicines: Veterinary medicineFDA approved animal drugs -> Active ingredient |
| Collision Cross Section | 173.2 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 融点 | 189-190°C |
| 引火点 | 9℃ |
| 貯蔵条件 | 2-8°C |
| 溶解度 | H2O: 25 mg/mL |
| 外観・状態 | 粉 |
| 色 | ホワイトからオフホワイト |
| pH | 3.5~5.0(100g/l,25℃) |
| BCS Class | 3/1 |
| 主な用途 | 医薬品（低分子化合物） |
| InChI | InChI=1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H31H |
| InChIKey | WIMWMKZEIBHDTH-UHFFFAOYSA-N |
| SMILES | N1(CCCN(C)C)C2C=CC=CC=2CCC2C=CC(Cl)=CC1=2.Cl |
| CAS データベース | 17321-77-6(CAS DataBase Reference) |
化学的特性
Off-White Solid
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 61 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 規制情報 | Hazard Traits - BioaccumulationEnvironmental PersistenceREACH registered substance: Clomipramine hydrochloride (EC: 241-344-3)Clomipramine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard |
| その他の安全情報 | IMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-, monohydrochloride: Human health tier I assessment |
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| Treatment | Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line, and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. (L1712) |
| 暴露経路 | Well absorbed from the GI tract following oral administration. Bioavailability is approximately 50% orally due to extensive first-pass metabolism. Bioavailability is not affected by food. Peak plasma concentrations occurred 2-6 hours following oral administration of a single 50 mg dose. The peak plasma concentration ranged from 56 ng/mL to 154 mg/mL (mean, 92 ng/mL). There are large interindividual variations in plasma concentrations occur, partly due to genetic differences in clomipramine metabolism. On average, steady state plasma concentrations are achieved in 1-2 weeks following multiple dose oral administration. Smoking appears to lower the steady-state plasma concentration of clomipramine, but not its active metabolite desmethylclomipramine. |
| 毒性の概要 | Clomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SRI), as the active main metabolite desmethyclomipramine acts preferably as an inhibitor of noradrenaline reuptake. &alpha |
用途
用途
三環系抗うつ作用化合物です。 クロミプラミンはイミプラミンのクロール誘 導体です。イミプラミンなどの他の三環系抗 うつ作用物質と比べ、ノルアドレナリン取り 込み阻害作用と比較してセロトニン取り込み 阻害作用を強く示します。
用途
三環系抗うつ作用化合物です。 クロミプラミンはイミプラミンのクロール誘 導体です。イミプラミンなどの他の三環系抗 うつ作用物質と比べ、ノルアドレナリン取り 込み阻害作用と比較してセロトニン取り込み 阻害作用を強く示します。
説明
Clomipramine is a tricyclic antidepressant, the 3-chlorinated derivative of imipramine . Like imipramine, clomipramine potently inhibits serotonin and norepinephrine reuptake (Kis = 7.4 and 96 nM, respectively). It also is an antagonist at histamine, muscarinic acetylcholine, α1-adrenergic, and dopamine receptors (Kds = 31, 37, 38, and 190 nM for H1, M1, α1, and D2, respectively).
使用
Serotonin reuptake inhibitor. Antidepressant; antiobsessional agent
一般的な説明
Clomipramine (Anafranil) is up to 50 times as potentas imipramine in some bioassays. This does not implyclinical superiority, but it might be informative about tricyclicand, possibly, other reuptake inhibitors. The chloro replacingthe H-substituent could increase potency by increasingdistribution to the CNS, but it is unlikely that this wouldgive the potency magnitude seen. It might be conjecturedthat an H-bond between the protonated amino group (as invivo) and the unshared electrons of the chloro substituent might stabilize a β-arylamine–like shape and give moreefficient competition for the transporter. The drug is anantidepressant. It is used in obsessive–compulsive disorder,an anxiety disorder that may have an element of depression.